COO, Shanghai Junshi Biosciences Co., Ltd.,
Dr. Feng obtained his bachelor’s degree in Biological Sciences and Technology from Tsinghua University (PRC) in 1997 and his Ph.D degree in Molecular Pharmacology from Albert Einstein College of Medicine in 2003, Yeshiva University (U.S.).
Dr. Feng Hui is the COO of Shanghai Junshi Biosciences Co., Ltd., with about 20 years’ industrial experience on R&D of innovative drugs. He has successively served with increasing roles at HumanZyme Inc., Medimmune Inc., a subsidiary of AstraZeneca, and TopAlliance Biosciences in United States. He is experienced in leading the drug R&D efforts in biotech/pharmaceutical companies and laying out the development strategies of innovative drugs, from concepts to IND and clinical trials to BLA.
His specialties include molecular design of antibody drug and protein therapeutics, humanization and affinity maturation, high-yield cell line establishment, CMC process development and technology transfer. He has participated in the development of nearly 20 mAbs with high technical barriers and intellectual property rights, authoring more than 30 academic papers and patents.